Very low tierNarrative ReviewCitation verified
How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease
David M Diamond, Uffe Ravnskov - Expert Review of Clinical Pharmacology, 2015
A critical commentary arguing that statins lower cholesterol but have not substantially improved cardiovascular outcomes, and that the appearance of benefit was created by reporting relative (rather than absolute) risk reduction while downplaying adverse effects.
Key findings
- Argues statins reduce cholesterol but have failed to substantially improve cardiovascular outcomes.
- Argues relative-risk-reduction reporting amplifies small absolute benefits.
- Argues adverse effects of statins have been minimised by trial directors.
Why this evidence tier (Very low)
- Risk of bias:
- Opinion/commentary by prominent cholesterol skeptics; selective in the evidence emphasised.
- Precision:
- Not an empirical estimate; no new data.
- Directness:
- Directly addresses the statin-benefit question but as argument, not new evidence.
- Publication bias:
- A position piece; presents the case for one side.
- Funding / COI:
- Authors are leading figures of the cholesterol-skeptic movement (Ravnskov founded THINCS); a clear directional interest.
Very low certainty as evidence: it is a critique, not data. Its value is in articulating the strongest skeptic argument (relative vs absolute risk, harms), which is partly legitimate even though the framing is contested.
- Population:
- Not applicable - critical commentary analysing published statin trials, not a primary study.
- Conflicts of interest:
- Authors are prominent cholesterol skeptics (Ravnskov founded the International Network of Cholesterol Skeptics); books and advocacy on the topic.
- Funding:
- Not reported on the fetched abstract.
Limitations
- Opinion/commentary, not a systematic analysis; no new data.
- Authors have a strong, declared directional position.